Business
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nThis acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry\n\n\n LOS ANGELES--(BUSINESS WIRE)--\nNiagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast (QUB), further strengthening the Company’s long-standing leadership and ownership position in NAD+ precursor intellectual property.\n\n\nThe acquired portfolio comprises the core body of patents underpinning the production, composition, and commercial use of NR, encompassing foundational composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights spanning multiple jurisdictions. Prior to this transaction, Niagen Bioscience previously held exclusive rights to these patents through long-standing licensing and joint ownership arrangements with QUB. With this acquisition, Niagen Bioscience now becomes the sole owner of this critical IP portfolio.\n\n\n“This transaction consolidates the most important intellectual property underlying our NR business into Niagen Bioscience outright,” said Rob Fried, Chief Executive Officer of Niagen Bioscience. “Composition of matter patents are the strongest form of IP protection, and owning this portfolio further protects Niagen Bioscience shareholders against infringers of all known forms of the greatest precursor to NAD, NR.”\n\n\nThe acquired patents include those previously disclosed by the Company in March 2025, including U.S. Patent No. 12,252,506, which covers the composition of matter for multiple NR salt forms—such as NR Malate and NR Tartrate—as well as other NR derivatives. Composition-of-matter patents are widely regarded as the strongest form of intellectual property protection because they cover the patented molecule itself and its defined forms, regardless of specific manufacturing pathways or methods of use.\n\n\nWith the acquisition of this portfolio, Niagen Bioscience gains enhanced financial, strategic and operational flexibility, greater control over the molecules it advances across current and fu...